Navigation Links
Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
Date:11/14/2013

BURLINGTON, Mass., Nov. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists across the EU5 (France, Germany, Italy, Spain and the United Kingdom) currently prescribe biologics—largely Pfizer's Enbrel or AbbVie's Humira— to approximately half of their psoriatic arthritis (PsA) patients who are treated with a disease-modifying antirheumatic drug (DMARD). By the end of 2016, 58 to 86 percent of respondents in each EU5 market expect to prescribe the fifth TNF-alpha inhibitor approved for PsA—UCB's Cimzia—compared with 30 to 58 percent who expect to prescribe Janssen's first-in-class IL-12/23 inhibitor Stelara. Notably fewer surveyed physicians expect to prescribe other emerging therapies by this time point, including Celgene's oral phosphodiesterase-4 inhibitor apremilast and Novartis's IL-17 inhibitor secukinumab.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The European Physician and Payer Forum report entitled Moving Beyond the TNF-Alpha Inhibitor Class in Psoriatic Arthritis in Europe: How Will Payers and Prescribers React to an Expanding Array of Treatment Options? also finds that while a novel mechanism of action may be a pricing lever, given the limited treatment options for TNF-alpha-refractory patients in PsA, manufacturers must strive to show evidence that sets their new brand apart from currently available TNF-alpha inhibitors in order to optimize market access opportunity for emerging brands. The rising health technology assessment (HTA) bar is illustrated by a lack of comparative data which contributed to Simponi's (Merck) ASMR of V (i.e. no added benefit versus marketed comparators) in France, stringent benefit assessments in Germany and the upcoming requirement for a therapeutic positioning report in Spain that will consider clinical benefit and degree of innovation when evaluating emerging drugs. As the cost constrained EU5 markets strive to draw out value for money, increasingly demanding HTA and increasingly complex pricing and reimbursement negotiations are evident in all markets.

The report also finds that the majority of surveyed rheumatologists expect the earliest reimbursed treatment line for Stelara will be as a second- or third-line therapy for conventional DMARD-refractory patients, and surveyed physicians do not foresee apremilast achieving a more favorable reimbursed treatment line, despite the drug's oral delivery and favorable safety profile.

"By the end of 2016, surveyed physicians across the EU5 report they will more likely position emerging therapies Stelara and apremilast in the third- or later-lines than in earlier lines of therapy for their PsA patients," said Decision Resources Analyst Kathryn Beane. "Surveyed physicians cite multiple reasons, including efficacy and a lack of a postmarketing efficacy and safety record (for apremilast) as factors constraining their prescribing."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
2. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
3. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
4. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
5. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
6. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
7. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
8. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
9. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
10. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
11. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Affairs leaders at pharmaceutical organizations are looking to either start or ... some companies have conducted a significant number of clinical trials in ... as India and China ... India are now requiring local clinical trials to win ... China and India are ...
(Date:2/12/2016)... , Feb. 12, 2016  Innophos Holdings, Inc. (NASDAQ: ... specialty ingredients, today announced that it will host a live ... ET to discuss its fourth quarter and full year 2015 ... The press release detailing fourth quarter and full year results ... close. --> --> ...
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon ...
(Date:2/12/2016)... Middletown, PA (PRWEB) , ... February 12, 2016 , ... ... year’s event will be held in Anaheim, CA at the Anaheim Convention Center. Almost ... they can see new therapy products in action, learn more about their chosen field ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology and ... the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards for ... Forum and Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, ...
(Date:2/12/2016)... ... 2016 , ... Every winter, someone is killed, injured or loses a home ... Center, part of the Allegheny Health Network, has partnered with Etna Volunteer Fire ... Need Space” campaign. , “Space Heaters Need Space” aims to bring awareness ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a family owned insurance ... is launching a cooperative charity drive with the Tarrant Area Food Bank in the ... individuals and families in need, the Tarrant County Food Bank offers hope and security ...
Breaking Medicine News(10 mins):